- Home
- CRSP vs BRKR Comparison
CRSP vs BRKR Comparison
Compare CRSP & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- BRKR
- Stock Information
- Founded
- CRSP 2013
- BRKR 1960
- Country
- CRSP Switzerland
- BRKR United States
- Employees
- CRSP N/A
- BRKR N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- BRKR Biotechnology: Laboratory Analytical Instruments
- Sector
- CRSP Health Care
- BRKR Industrials
- Exchange
- CRSP Nasdaq
- BRKR Nasdaq
- Market Cap
- CRSP 4.9B
- BRKR 5.3B
- IPO Year
- CRSP 2016
- BRKR 2000
- Fundamental
- Price
- CRSP $56.26
- BRKR $30.91
- Analyst Decision
- CRSP Buy
- BRKR Buy
- Analyst Count
- CRSP 16
- BRKR 11
- Target Price
- CRSP $72.27
- BRKR $50.00
- AVG Volume (30 Days)
- CRSP 1.9M
- BRKR 4.3M
- Earning Date
- CRSP 11-04-2025
- BRKR 11-04-2025
- Dividend Yield
- CRSP N/A
- BRKR 0.65%
- EPS Growth
- CRSP N/A
- BRKR N/A
- EPS
- CRSP N/A
- BRKR 0.52
- Revenue
- CRSP $38,050,000.00
- BRKR $3,442,800,000.00
- Revenue This Year
- CRSP N/A
- BRKR $4.44
- Revenue Next Year
- CRSP $348.18
- BRKR $1.71
- P/E Ratio
- CRSP N/A
- BRKR $59.35
- Revenue Growth
- CRSP N/A
- BRKR 10.36
- 52 Week Low
- CRSP $30.04
- BRKR $28.53
- 52 Week High
- CRSP $71.13
- BRKR $72.94
- Technical
- Relative Strength Index (RSI)
- CRSP 54.66
- BRKR 41.52
- Support Level
- CRSP $51.63
- BRKR $30.31
- Resistance Level
- CRSP $55.59
- BRKR $34.22
- Average True Range (ATR)
- CRSP 2.06
- BRKR 1.34
- MACD
- CRSP 0.27
- BRKR 0.05
- Stochastic Oscillator
- CRSP 96.36
- BRKR 32.65
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.